India’s supreme court has rejected an appeal from Swiss pharmaceutical giant Novartis to patent a new version of its anticancer drug, Glivec.
The court ruled on 1 April that the new version of the drug is not sufficiently different from the original, although the new version has been patented in many other countries, including the United States, Russia and China. The decision concluded legal proceedings that began in 2006.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.